Evolocumab for hypercholesterolemia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 9 Jan 2013: Trial registered, NCT01764633
  2. 8 Feb 2013: Trial started, NCT01764633
  3. 4 Aug 2014: Trial registered, NCT02207634
  4. 10 Sep 2014: Trial started, NCT02207634
  5. 16 Aug 2016: Trial registered, NCT02867813
  6. 2 Sep 2016: Trial started, NCT02867813

The trials

NCT01652703: A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

State
Completed
Phase
Phase 2
People
310 taking part
Started
10 Jul 2012
Primary completion
14 May 2013
Arms
Evolocumab 70 mg Q2W, Evolocumab 140 mg Q2W, Evolocumab 280 mg Q4W, Evolocumab 420 mg Q4W
Results
Posted on the registry
  1. 10 Jul 2012: Trial started
  2. 30 Jul 2012: Trial registered
  3. 5 Oct 2015: Trial results posted
  4. 28 Nov 2018: Trial completed

NCT01764633: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

State
Completed
Phase
Phase 3
People
27,564 taking part
Started
8 Feb 2013
Primary completion
11 Nov 2016
Arms
Evolocumab
Results
Posted on the registry
  1. 9 Jan 2013: Trial registered
  2. 8 Feb 2013: Trial started
  3. 11 Nov 2016: Trial completed
  4. 15 Feb 2018: Trial results posted

NCT02207634: Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

State
Completed
Phase
Phase 3
People
1,974 taking part
Started
10 Sep 2014
Primary completion
11 Nov 2016
Arms
Evolocumab
Results
Posted on the registry
  1. 4 Aug 2014: Trial registered
  2. 10 Sep 2014: Trial started
  3. 11 Nov 2016: Trial completed
  4. 16 Jan 2018: Trial results posted

NCT02867813: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

State
Completed
Phase
Phase 3
People
5,035 taking part
Started
2 Sep 2016
Primary completion
21 Mar 2022
Arms
evolocumab (AMG 145)
Results
Posted on the registry
  1. 16 Aug 2016: Trial registered
  2. 2 Sep 2016: Trial started
  3. 21 Mar 2022: Trial completed
  4. 28 Feb 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Evolocumab 140 MG/ML [Repatha], Repatha.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.